AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36755110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital rule-out with POC troponin measurement
Number of subjects: 863
Study 36755110 — intervention group
Group type: COMPARATOR
Intervention: Direct transfer to the ED
Number of subjects: 863
Study 36755187 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health center model
Number of subjects: 0
Study 36755187 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36755231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0
Study 36755231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0
Study 36755231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36755279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception micronutrient supplementation
Number of subjects: 1599
Study 36755288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 36755288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of antioxidant responses
Number of subjects: 0
Study 36755328 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue standard TNFi dosing
Number of subjects: 198
Study 36755328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed longer dosing intervals of TNFi
Number of subjects: 198
Study 36755328 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop TNFi
Number of subjects: 198
Study 36755418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 36755418 — intervention group
Group type: COMPARATOR
Intervention: Conventional (noncellular) therapies
Number of subjects: 0
Study 36756354 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD-NET
Number of subjects: 0
Study 36756354 — intervention group
Group type: COMPARATOR
Intervention: Online supportive psychotherapy
Number of subjects: 0
Study 36756676 — intervention group
Group type: EXPERIMENTAL
Intervention: Enavogliflozin 0.3 mg/day
Number of subjects: 200
Study 36756676 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 200
Study 36756808 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal inactivated influenza vaccine
Number of subjects: 784
Study 36756808 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic exposure
Number of subjects: 784
Study 36756843 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital peer support intervention via the Acceset platform
Number of subjects: 100
Study 36756874 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 786
Study 36756874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study 36756899 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (recombinant activated factor VIIa; 80 μg/kg)
Number of subjects: 50
Study 36756899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 36756959 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 905
Study 36757197 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus carboplatin (nab-P/C)
Number of subjects: 408
Study 36757197 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 408
Study 36757197 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 408
Study 36757300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assessment methods for rehabilitation needs
Number of subjects: 0
Study 36757318 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (2-g oral dose)
Number of subjects: 29278
Study 36757318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29278
Study 36757390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (50 mg)
Number of subjects: 56
Study 36757390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib generic (50 mg)
Number of subjects: 56
Study 36757424 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic stereotactic body radiotherapy (SBRT) with 35 Gy in 5 fractions
Number of subjects: 85
Study 36757445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus DEB-TACE
Number of subjects: 60
Study 36757536 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat 100 mg
Number of subjects: 294
Study 36757536 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat 500 mg
Number of subjects: 294
Study 36757536 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 294
Study 36757568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 36757568 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 36757568 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus (64% of cultures)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (42%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-sensitive Staphylococcus aureus (22%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic gram-negative infections (35%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobes (31%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungi (6%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-resistant bacteria (17%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure aerobic gram-positive cultures (50%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic gram-positive/gram-negative (8%)
Number of subjects: 100
Study 36757611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure gram-negative cultures (6%)
Number of subjects: 100
Study 36757689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy, administered as a single subretinal injection after vitrectomy surgery, with the 4 highest doses administered to 12 participants.
Number of subjects: 121
Study 36757689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy (4 highest doses).
Number of subjects: 121
Study 36757689 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes from the XIRIUS study and untreated subgroup from the XOLARIS study.
Number of subjects: 121
Study 36757690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid rectal spacer
Number of subjects: 201
Study 36757690 — intervention group
Group type: COMPARATOR
Intervention: Control (no spacer)
Number of subjects: 201
Study 36757696 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride with fluoride varnish
Number of subjects: 2998
Study 36757696 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer sealants with fluoride varnish
Number of subjects: 2998
Study 36757706 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 143
Study 36757706 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy (high-dose cytarabine)
Number of subjects: 143
Study 36757706 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 143
Study 36757755 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban plus alteplase (n=402); intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% as 1-minute bolus, remaining infused over 1 hour)
Number of subjects: 808
Study 36757755 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone (n=415)
Number of subjects: 808
Study 36757755 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban plus alteplase
Number of subjects: 808
Study 36757755 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 808
Study 36757770 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlate smartphone app
Number of subjects: 104
Study 36757770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 36757779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Home Severity Index-Pressure Injury with severity dimensions and Worst-Braden score
Number of subjects: 1015
Study 36757779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Home Severity Index-Pressure Injury
Number of subjects: 1015
Study 36757859 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless-VVI
Number of subjects: 9858
Study 36757859 — intervention group
Group type: COMPARATOR
Intervention: Transvenous-VVI
Number of subjects: 9858
Study 36758013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 4439
Study 36758013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4439
Study 36758420 — intervention group
Group type: EXPERIMENTAL
Intervention: farletuzumab + chemotherapy
Number of subjects: 214
Study 36758420 — intervention group
Group type: COMPARATOR
Intervention: placebo + chemotherapy
Number of subjects: 214
Study 36758570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (625 mg overencapsulated tablets, starting dose of two capsules twice daily for 12 days, titrated to effect during the first 5 days)
Number of subjects: 168
Study 36758570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 168
Study 36758570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 36758572 — intervention group
Group type: EXPERIMENTAL
Intervention: BIF-A1
Number of subjects: 399
Study 36758572 — intervention group
Group type: EXPERIMENTAL
Intervention: BIF-A2
Number of subjects: 399
Study 36758572 — intervention group
Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 399
Study 36758572 — intervention group
Group type: EXPERIMENTAL
Intervention: BIF
Number of subjects: 399
Study 36758612 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion (5.5% of patients)
Number of subjects: 5213
Study 36758612 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulants (92.1% of patients)
Number of subjects: 5213
Study 36758612 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (75.6% at discharge)
Number of subjects: 5213
Study 36758612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (6.7% at discharge)
Number of subjects: 5213
Study 36758710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy lifestyle intervention (16 weeks)
Number of subjects: 199
Study 36758710 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 199
Study 36758710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy lifestyle intervention
Number of subjects: 199
Study 36758710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy weight loss (independent of group)
Number of subjects: 199
Study 36758710 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥5% weight loss before conception (independent of group)
Number of subjects: 199
Study 36758712 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training (SOPT)
Number of subjects: 60
Study 36758712 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study 36758740 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified High-Intensity Interval Training (HIIT) - short bouts (≤ 90 seconds) at 80%-90% of peak oxygen consumption (VO2)
Number of subjects: 20
Study 36758740 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) - 20 minutes at 50%-60% of VO2
Number of subjects: 20
Study 36758935 — intervention group
Group type: EXPERIMENTAL
Intervention: PE with PE Coach
Number of subjects: 124
Study 36758935 — intervention group
Group type: COMPARATOR
Intervention: PE without PE Coach
Number of subjects: 124
Study 36759013 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles
Number of subjects: 30
Study 36759013 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus triplet chemotherapy
Number of subjects: 30
Study 36759296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaborative radiotherapy planning
Number of subjects: 37
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: RMDQ
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Behavior
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Interference
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ
Number of subjects: 328
Study 36759316 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAQ
Number of subjects: 328
Study 36759606 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal tract (CST) sparing
Number of subjects: 748
Study 36759606 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment strategies for muscle-specific motor recovery
Number of subjects: 748
Study 36759673 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus neoadjuvant chemotherapy (NAC)
Number of subjects: 37
Study 36759706 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV with rate settings multiplied by three
Number of subjects: 50
Study 36759706 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV with rate settings divided by three
Number of subjects: 50
Study 36759720 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin/pegylated liposomal doxorubicin (TP) followed by platinum therapy at relapse
Number of subjects: 617
Study 36759720 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/pegylated liposomal doxorubicin (CP)
Number of subjects: 617
Study 36759766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 27
Study 36759766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 36759788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersensitivity pneumonitis patients with pulmonary hypertension (PH)
Number of subjects: 60
Study 36759858 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for remote monitoring
Number of subjects: 310
Study 36759858 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 310
Study 36759873 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with essential amino acids (EAA) and intermediates of the tricarboxylic acid (TCA) cycle (citrate, malate, succinate)
Number of subjects: 92
Study 36759873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 36759873 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with EAA and TCA intermediates
Number of subjects: 92
Study 36759893 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an AI-decision aid
Number of subjects: 0
Study 36759893 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36759901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal infusion of neural stem cells (NSCs) with nasal patches and rehabilitation therapy
Number of subjects: 25
Study 36759901 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy only
Number of subjects: 25
Study 36759902 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with high fidelity score
Number of subjects: 0
Study 36759902 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with high fidelity to advance care planning
Number of subjects: 0
Study 36759902 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with low fidelity to communication tools (e.g., ISBAR)
Number of subjects: 0
Study 36759915 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-PCIT (AI-PCIT) group
Number of subjects: 100
Study 36759915 — intervention group
Group type: COMPARATOR
Intervention: PCIT-sham biometric group (Control)
Number of subjects: 100
Study 36760521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat diet with exercise
Number of subjects: 57
Study 36760521 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate high-fat diet without exercise
Number of subjects: 57
Study 36760521 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet with exercise
Number of subjects: 57
Study 36760521 — intervention group
Group type: COMPARATOR
Intervention: Normal diet without exercise
Number of subjects: 57
Study 36760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered self-management intervention for eight weeks duration
Number of subjects: 612
Study 36760576 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 612
Study 36760605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 164
Study 36760605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% compound lidocaine hydrochloride injection
Number of subjects: 164
Study 36760605 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 164
Study 36760785 — intervention group
Group type: EXPERIMENTAL
Intervention: EDL app
Number of subjects: 100
Study 36760785 — intervention group
Group type: COMPARATOR
Intervention: Injury prevention text messages
Number of subjects: 100
Study 36760794 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS/SS
Number of subjects: 36
Study 36760794 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS/sham SS
Number of subjects: 36
Study 36760794 — intervention group
Group type: EXPERIMENTAL
Intervention: sham rTMS/SS
Number of subjects: 36
Study 36760794 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS/Sham SS
Number of subjects: 36
Study 36760794 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 rTMS and SS alone or in combination
Number of subjects: 36
Study 36760794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of S1 rTMS and SS
Number of subjects: 36
Study 36761135 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual plus guided self-help stress management guide (Doing What Matters in Times of Stress, DWM) and a five-session cognitive behavioral intervention (Problem Management Plus, PM+)
Number of subjects: 212
Study 36761135 — intervention group
Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 212
Study 36761135 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual plus DWM and PM+
Number of subjects: 212
Study 36761185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 62
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations met
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk physical activity profile
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 60-69 years
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 70-79 years
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 80+ years
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30-39
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 40+
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score 1-2
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score 3+
Number of subjects: 768
Study 36761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 768
Study 36761410 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of moderate intensity aerobic exercise
Number of subjects: 136
Study 36761410 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study 36761900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal photodynamic therapy (PDT)
Number of subjects: 75
Study 36761900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 36761922 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence (AI) based algorithm using ECG signals collected through a non-invasive device.
Number of subjects: 0
Study 36761922 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive wearable device for recording physiological data and respiratory rate.
Number of subjects: 0
Study 36761922 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) AI algorithm.
Number of subjects: 0
Study 36761922 — intervention group
Group type: COMPARATOR
Intervention: Previous pilot results based on four healthy adults.
Number of subjects: 0
Study 36761980 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary adenocarcinomas
Number of subjects: 33
Study 36761980 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary squamous cell tumors
Number of subjects: 33
Study 36762424 — intervention group
Group type: COMPARATOR
Intervention: Peak hsTnI <75 ng/L
Number of subjects: 4553
Study 36762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hsTnI 75 ng/L to <1000 ng/L
Number of subjects: 4553
Study 36762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥1000 ng/L
Number of subjects: 4553
Study 36762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L
Number of subjects: 4553
Study 36762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L with ischemic features
Number of subjects: 4553